Size Matters: NIH Patents Brain-Targeting Drug Tech Exclusively
Published Date: 4/22/2025
Notice
Summary
The National Cancer Institute is planning to give Sangam Lifesciences an exclusive patent license for a cool new drug delivery technology that targets the brain and lymph system based on size. This means Sangam gets special rights to develop and sell this invention, which could speed up better treatments. If you’re in biotech or healthcare, keep an eye out—this deal could shake things up soon!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Exclusive NIH Patent License Award
The National Cancer Institute is considering granting an exclusive patent license to Sangam Lifesciences, Inc., a company in Denver, Colorado, for a macromolecular drug delivery technology that targets brain and lymphatic distribution. The license would allow Sangam to practice the inventions embodied in the patent applications listed in the notice's Supplementary Information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2025-06876, Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities
Some companies want to start or buy businesses that do activities related to banking but aren’t banks themselves. The Federal Reserve is checking these plans and asking the public to share their thoughts by May 7, 2025. This helps keep banking safe and sound while letting companies grow in new ways across the U.S.
Next: 2025-06879, National Center for Advancing Translational Sciences; Notice of Closed Meeting
The National Center for Advancing Translational Sciences is holding a private meeting on May 14-15, 2025, to review secret contract proposals about developing new drug products. This meeting affects companies and researchers involved in drug development and keeps sensitive info safe. No public money changes are announced, but the decisions could impact future drug research funding.